Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Conclusions We did not find evidence for an increased risk of cardiovascular outcomes with tofacitinib in patients with RA treated in the real-world setting; however, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors. Trial registration number NCT04772248.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD, Rheumatoid arthritis Source Type: research